Alpine Associates Management Inc. Has $115.90 Million Stock Position in Catalent, Inc. (NYSE:CTLT)

Alpine Associates Management Inc. increased its position in Catalent, Inc. (NYSE:CTLT) by 3.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 2,061,251 shares of the company’s stock after buying an additional 75,700 shares during the quarter. Catalent makes up about 5.5% of Alpine Associates Management Inc.’s investment portfolio, making the stock its 5th largest position. Alpine Associates Management Inc.’s holdings in Catalent were worth $115,904,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CTLT. Victory Capital Management Inc. boosted its holdings in Catalent by 90.5% in the 4th quarter. Victory Capital Management Inc. now owns 33,940 shares of the company’s stock worth $1,525,000 after buying an additional 16,120 shares during the period. Principal Securities Inc. bought a new position in Catalent in the 4th quarter worth $56,000. Jump Financial LLC purchased a new stake in Catalent in the 4th quarter worth $348,000. Dimensional Fund Advisors LP lifted its stake in Catalent by 29.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,639,197 shares of the company’s stock worth $73,655,000 after purchasing an additional 376,931 shares in the last quarter. Finally, Panagora Asset Management Inc. lifted its stake in Catalent by 78.9% in the 4th quarter. Panagora Asset Management Inc. now owns 21,766 shares of the company’s stock worth $978,000 after purchasing an additional 9,600 shares in the last quarter.

Catalent Stock Down 0.1 %

Shares of NYSE CTLT opened at $59.62 on Monday. The firm’s 50-day moving average price is $59.21 and its 200-day moving average price is $57.11. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of -9.77, a P/E/G ratio of 1.88 and a beta of 1.15. Catalent, Inc. has a 12-month low of $31.80 and a 12-month high of $61.20.

Analysts Set New Price Targets

CTLT has been the topic of several research analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. StockNews.com initiated coverage on shares of Catalent in a research note on Tuesday, September 10th. They issued a “sell” rating on the stock. Barclays boosted their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Catalent currently has an average rating of “Hold” and an average target price of $58.08.

Insider Buying and Selling

In related news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at approximately $10,431,133.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Scott Gunther sold 666 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The disclosure for this sale can be found here. Insiders have sold 13,409 shares of company stock valued at $782,923 in the last ninety days. 0.31% of the stock is owned by company insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.